Abstract
A previous study of the metabolic fate of cinromide (3-bromo-N-ethylcinnamamide) in rhesus monkey established that half of a dose is metabolized byN-deethylation to an active metabolite, 3-bromocinnamamide. Both cinromide and its proximal metabolite can be metabolized by amide hydrolysis to a second metabolite, 3-bromocinnamic acid, resulting in a triangular metabolic problem. This investigation was undertaken to distinguish between these two nonexclusive possibilites. A preliminary study was carried out to characterize the pharmacokinetics of 3-bromocinnamic acid. In the main study, six monkeys received an intravenous dose of cinromide, 3-bromocinnamamide, and 3-bromocinnamic acid in a randomized order. The time courses of compound administered and corresponding metabolites were followed. The following fractions of dose metabolized (mean±SD) were obtained: cinromide to 3-bromocinnamide: 0.53 ±0.24; 3-bromocinnamamide to 3-bromocinnamic acid: 0.53 ±0.21; cinromide to 3-bromocinnamic acid directly: 0.48 ±0.32. Thus, it was found that 3-bromocinnamic acid is formed directly from cinromide and from 3-bromocinnamamide. Also, as primary metabolites, 3-bromocinnamic acid and 3-bromocinamamide account for all of a cinromide dose with a mean value of 1.00±0.34. The observed variability in these fractions metabolized was explained by the fact that in the solution of the triangular metabolic problem, three clearances are assumed to remain constant over three studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. A. Lane and R. H. Levy. Pharmacokinetic relationships between cinromide and its metabolites in the rhesus monkey1: 3-Bromocinnamamide, an active metaboiite.J. Pharm. Sci. 72:493–496 (1983).
J. S. Lockard, R. H. Levy, L. L. DuCharme, and W. C. Congdon. Experimental anticonvulsant cinromide in monkey model: Preliminary efficacy.Epilepsia 20:339–350 (1979).
J. S. Lockard, R. H. Levy, L. L. DuCharme, and W. C. Congdon. Cinromide's metabolite in monkey: Gastric administration and seizure control.Epilepsia 21:177–182 (1980).
R. L. DeAngelis, M. M. Robinson, A. R. Brown, T. E. Johnson, and R. M. Welch. Quantitation of the anticonvulsant cinromide (3-bromo-N-ethylcinnamamide) and its major plasma metabolites by thin-layer chromatography.J. Chromatogr. 221:353–360 (1980).
L. A. Lockman, A. D. Rothner, G. Erenberg, F. W. Wright, G. Cloutier, and E. H. Geiger. Cinromide in the treatment of Lennox-Gastaut syndrome. Presented at the American Epilepsy Society Meeting, San Diego, California, 1980.
A. J. Wilensky, E. A. Lane, R. H. Levy, L. M. Ojemann, and P. N. Friel. Differential kinetics of cinromide and two metabolites in epileptic patients.Eur. J. Clin. Pharmacol. 21:149–153 (1981).
H.-S. Lin, R. H. Levy, E.A. Lane, and W. P. Gordon. Variability in the determination of the fraction metabolized in a triangular metabolic problem and its resolution with stable isotope methodology.J. Pharm. Sci. 73:285–287 (1984).
L. Z. Benet and R. L. Galeazzi. Noncompartmental determination of the steady-state volume of distribution.J. Pharm. Sci. 68:1071–1074 (1979).
S. A. Kaplan, M. L. Jack, S. Cotler, and K. Alexander. Utilization of area under the curve to elucidate the disposition of an extensively biotransformed drug.J. Pharmacokin. Biopharm. 1:201–216 (1973).
K. S. Pang. Metabolite pharmacokinetics: The area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and heptically cleared drugs and metabolites.J. Pharmacokin. Biopharm. 9:477–487 (1981).
W. J. Dickerson and M. B. Brown (eds.).Biomedical Computer Programs-P Series, Berkeley, California, 1977, pp. 540–601.
D. G. Kleinbaum and C. C. Kupper.Applied Regression Analysis and Other Multivariate Methods. Doxbury Press, Belmont, California, 1978, pp. 264–277.
P. A. J. Reilly, T. Inaba, D. Kader, and L. Endrenyl, Enzyme induction following a single dose of amobarbital in dogs.J. Pharmacokin. Biopharm. 6:305–313 (1978).
P. J. McNamara, G. Levy, and M. Gibaldi. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.J. Pharmacokin. Biopharm. 7:195–206 (1979).
K. S. Pang and K. C. Kwan, Methods and assumptions in the kinetic estimation of metabolite formation.Drug Metab. Dispos. 11:79–84 (1983).
E. A. Lane and R. H. Levy,In vivo evaluation of Michaelis-Menten constant-for a medium extraction ratio drug: Application to cinromide in rhesus monkey.J. Pharm. Sci. 72:1352–1354 (1983).
K. S. Pang and J. R. Gillette, Sequential first-pass elimination of a metabolite from a precursor.J. Pharmacokin. Biopharm. 7:275–290 (1979).
Author information
Authors and Affiliations
Additional information
This paper represents #2 in the series of Pharmacokinetic Relationships of Cinromide and its Metabolites in Rhesus Monkey. Supported in part by National Institutes of Health contract NO1-NS-1-2282.
Rights and permissions
About this article
Cite this article
Lane, E.A., Levy, R.H. Fractions metabolized in a triangular metabolic system: Cinromide and two metabolites in the rhesus monkey. Journal of Pharmacokinetics and Biopharmaceutics 13, 373–386 (1985). https://doi.org/10.1007/BF01061475
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01061475